Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Tourmaline Bio (TRML)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 41,310,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation, called Facilitated Allo-HSCT Therapy, that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. Co.'s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 105,000 149,150 345,094
Total Buy Value $0 $3,335,270 $3,893,256 $4,632,634
Total People Bought 0 3 5 7
Total Buy Transactions 0 3 10 17
Total Shares Sold 0 0 250,003 1,062,376
Total Sell Value $0 $0 $618,955 $2,712,339
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 10 28
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 89
  Page 3 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ildstad Suzanne Director   –       •      –    2023-02-16 4 S $2.06 $6,040 D/D (2,939) 3,078,507     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-12-30 4 A $0.87 $3 D/D 4 590,193     -
   Fenton Mary Kay Chief Financial Officer   •       –      –    2022-09-10 4 A $0.00 $0 D/D 80,000 81,000     -
   Krieger Nancy Chief Medical Officer   •       –      –    2022-09-10 4 A $0.00 $0 D/D 80,000 330,233     -
   Zdanowski Michael Chief Technology Officer   •       –      –    2022-09-10 4 A $0.00 $0 D/D 120,000 121,470     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-09-10 4 A $0.00 $0 D/D 80,000 590,189     -
   Ildstad Suzanne Chief Scientific Officer   •       –      –    2022-08-22 4 S $2.80 $1,470,000 D/D (525,000) 3,081,446     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-07-29 4 B $4.25 $167,374 D/D 39,382 508,680 2.81     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-07-28 4 B $4.25 $13,133 D/D 3,090 469,298 2.81     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-07-26 4 B $4.24 $23,439 D/D 5,528 466,208 2.81     -
   Nader Francois Director   –       •      –    2022-07-25 4 A $0.00 $0 I/I 138,500 386,932     -
   Nader Francois Director   –       •      –    2022-07-25 4 D $0.00 $0 D/D (138,500) 0     -
   Requadt Scott Chief Executive Officer   •       •      –    2022-07-22 4 B $3.75 $35,412 D/D 9,444 460,680 2.81     -
   Nader Francois Director   –       •      –    2022-07-21 4/A D $0.00 $0 I/I (248,432) 147,255     -
   Nader Francois Director   –       •      –    2022-07-21 4 B $3.72 $135,780 D/D 36,500 138,500 2.39     -
   Nader Francois Director   –       •      –    2022-07-21 4 A $0.00 $0 I/I 248,432 248,432     -
   Nader Francois Director   –       •      –    2022-07-21 4 D $0.00 $0 I/I (248,432) 87,735     -
   Nader Francois Director   –       •      –    2022-07-20 4 B $3.62 $188,240 D/D 52,000 102,000 2.39     -
   Nader Francois Director   –       •      –    2022-07-19 4 B $3.52 $176,000 D/D 50,000 50,000 2.39     -
   Zdanowski Michael Chief Technology Officer   •       –      –    2021-12-31 4 A $13.00 $19,110 D/D 1,470 1,470     -
   Fenton Mary Kay Chief Financial Officer   •       –      –    2021-12-31 4 A $13.00 $13,000 D/D 1,000 1,000     -
   Requadt Scott Chief Executive Officer   •       •      –    2021-12-31 4 A $13.00 $19,110 D/D 1,470 451,236     -
   Nader Francois Director   –       •      –    2021-12-15 4 GD $0.00 $0 I/I 59,520 336,167     -
   Ildstad Suzanne Chief Scientific Officer   •       –      –    2021-11-17 4 GA $0.00 $0 I/I 1,200,000 1,200,000     -
   Ildstad Suzanne Chief Scientific Officer   •       –      –    2021-11-17 4 GD $0.00 $0 D/D 1,200,000 3,606,446     -
  89 Records found
  1  2  3  4   
  Page 3 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us